Real World Use, Effectiveness and Safety of Teprotumumab among Thyroid Eye Disease Patients treated in China BOAO Pilot Zone: A Retrospective Cohort Study (20240345)

Study identification

• EU PAS number:
  EUPAS1000000625
• Study ID:
  1000000625
• Official title and acronym:
  Real World Use, Effectiveness and Safety of Teprotumumab among Thyroid Eye Disease Patients treated in China BOAO Pilot Zone: A Retrospective Cohort Study (20240345)
• DARWIN EU® study:
  No
• Study countries:
  China
• Study description:
  No information provided.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Amgen

United States

Study timelines

Date when funding contract was signed

Planned:12/05/2025

Actual:12/05/2025

Study start date

Planned:30/07/2025

Actual:02/07/2025

Data analysis start date

Planned:30/09/2025

Actual:15/09/2025

Date of final study report

Planned:28/02/2026

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable